MedTrace Logo

NTS-WBRT in Brain Metastases

NCT05013892 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-04-16

No results posted yet for this study

Summary

This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT).

This research study involves:

* NTS-WBRT (normal tissue sparing whole brain radiation therapy)
* Memantine standard of care drug

Conditions

Interventions

RADIATION

NTS-WBRT (normal tissue sparing whole brain radiation therapy)

Radiation

DRUG

Memantine

Capsule, taken orally

Sponsors & Collaborators

Principal Investigators

  • Helen A Shih, MD, MS, MPH · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-08
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05013892 on ClinicalTrials.gov